Cellectis S.A. financial data

Symbol
CLLS on Nasdaq
Location
Paris, Lle De France
Fiscal year end
31 December
Latest financial report
6-K/A - Q2 2024 - 11 Sep 2024

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense $23,518,000 USD 5.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets $407,147,000 USD 79%
Liabilities $258,537,000 USD